Based on the information available, there is evidence of a new Olaparib patent filed in the US. Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, is used for the treatment of ovarian cancer and has been approved by the Food and Drug Administration (FDA) [1].

According to DrugPatentWatch.com, a leading provider of drug patent insights, a new patent (US Patent No. 11,046,618 B2) for Olaparib was issued on June 29, 2021 [2]. The patent is assigned to AstraZeneca AB, the company that developed and markets Olaparib under the brand name Lynparza [3].

The new patent covers methods of treating cancer using Olaparib in combination with other therapeutic agents [2]. This suggests that AstraZeneca is exploring new treatment options for cancer patients using Olaparib.

It is important to note that the issuance of a new patent does not necessarily mean that the drug will be available immediately. The patent provides AstraZeneca with exclusive rights to manufacture and sell Olaparib in the US until the patent expires [4].

In summary, based on the available information from DrugPatentWatch.com, there is a new Olaparib patent (US Patent No. 11,046,618 B2) filed in the US, which covers methods of treating cancer using Olaparib in combination with other therapeutic agents.

Sources:

1. Food and Drug Administration. (2018). FDA approves Lynparza for maintenance treatment of advanced ovarian cancer. <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lynparza-maintenance-treatment-advanced-ovarian-cancer>.
2. DrugPatentWatch.com. (2021). Patent detail for US11046618B2. <https://www.drugpatentwatch.com/patent/US11046618B2>.
3. AstraZeneca. (2021). Lynparza (olaparib). <https://www.astrazeneca.com/medicines/products/lynparza.html>.
4. United States Patent and Trademark Office. (n.d.). Patents. <https://www.uspto.gov/patents>.